Liposomal bupivacaine plus bupivacaine hydrochloride versus bupivacaine hydrochloride alone for post-craniotomy scalp nerve block analgesia

Phase 4, randomised trial in Post-craniotomy pain comparing Bupivacaine hydrochloride group with Liposomal bupivacaine plus bupivacaine hydrochloride group (2 arms). Primary endpoint: Area under the curve of resting numerical rating scale pain scores from 12 to 72 hours after completion of the scalp nerve block. Planned start Oct 2026; status: not yet recruiting.